

2013

# Tracking and evaluation on the individual and enterprise level

Jae Allen

*Washington University School of Medicine in St. Louis*

Bobbi J. Carothers

*Washington University in St Louis*

Kristi L. Holmes

*Washington University School of Medicine in St. Louis*

Elizabeth Palombo

*Washington University School of Medicine in St. Louis*

Cathy C. Sarli

*Washington University School of Medicine in St. Louis*

Follow this and additional works at: [http://digitalcommons.wustl.edu/becker\\_pubs](http://digitalcommons.wustl.edu/becker_pubs)

---

## Recommended Citation

Allen, Jae; Carothers, Bobbi J.; Holmes, Kristi L.; Palombo, Elizabeth; and Sarli, Cathy C., "Tracking and evaluation on the individual and enterprise level." 4th Annual Vivo Conference, August 14-16, 2013, St. Louis, MO. 2013. Paper 40.  
[http://digitalcommons.wustl.edu/becker\\_pubs/40](http://digitalcommons.wustl.edu/becker_pubs/40)

This Teaching Material is brought to you for free and open access by the Becker Medical Library at Digital Commons@Becker. It has been accepted for inclusion in Becker Library Publications and Presentations by an authorized administrator of Digital Commons@Becker. For more information, please contact [engeszer@wustl.edu](mailto:engeszer@wustl.edu).




Institute of **C**linical and  
**T**ranslational **S**ciences

 **Washington University in St. Louis**  
SCHOOL OF MEDICINE

# Tracking and Evaluation on the Individual and Enterprise Level

Washington University Institute of Clinical and Translational Sciences  
Tracking & Evaluation team: WU ICTS Administrative Core, WU Clinical  
Research Training Center, WU Center for Public Health Systems  
Science, and Bernard Becker Medical Library



Center for Public Health  
Systems Science

**CLINICAL RESEARCH**  
TRAINING CENTER (CRTC)

**BERNARD BECKER**  
MEDICAL LIBRARY  
delivering knowledge, informing decisions

# Introductions

ICTS T&E

WORKSHOP ATTENDEES

# Acknowledgement

Supported by the Clinical and Translational Science Award (CTSA) program of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH)  
Grant Numbers UL1 TR000448, KL2 TR000450, TL1 TR000449

---

# Introduction to CTSAs and ICTS

Kristi L. Holmes, PhD

Hold on to your hats.

---

# Objectives

1. Understand the **activities, tools, and logistics for assessing** research productivity
2. Have a better understanding of **evaluation activities for groups or individuals** anywhere along the academic career trajectory, from scholars to tenured faculty
3. Understand **data sources** and **how they can be leveraged** in assessment of impact and research discovery
4. Understand **how to tell the story of research impact** and **strategies to enhance research impact**






Institute of **C**linical and  
**T**ranslational **S**ciences



# ***Translational Research***

# Working Together, Sharing a Vision

The CTSA Consortium aims to improve human health by transforming the research and training environment to enhance the efficiency and quality of clinical and translational research.



The CTSA consortium has *five Strategic Goals*:

- National Clinical and Translational Research Capability
- The Training and Career Development of Clinical and Translational Scientists
- Consortium-Wide Collaborations
- The Health of our Communities and the Nation
- T1 Translational Research





# ICTS Strategic Goals

- Transform our **research support infrastructure** to foster multidisciplinary clinical & translational research
- Expand & enhance clinical & translational **research education**
- Promote & facilitate **regional & national partnerships**



# ICTS Tracking & Evaluation Goals


- Track and monitor the **integration of services and activities** of the overall ICTS, and ICTS cores. *(ICTS Goal 1)*
  - Assess the growth in **scientific capacity** resulting from the ICTS education and training activities *(ICTS Goal 1)*
  - Assess the growth in scientific and institutional **collaborations and communication** as a function of ICTS activities. *(ICTS Goal 3)*
  - Evaluate the **impact** of the ICTS on scientific and scholarly work *(ICTS Goal 2)*
-

# An interdisciplinary approach to tracking and evaluation

- **AC:** ICTS Administrative Core
- **Becker:** Bernard Becker Medical Library
- **CPHSS:** Center for Public Health Systems Science
- **CRTC:** Clinical Research Training Center



# T&E Reports to ICTS Governance




- Accountable to ICTS Director
- Periodic reports to all levels of governance as well as NIH/NCATS

# What to count? What matters?

IOM CTSA Report released 6/25/13

## Areas of emphasis:

- *Formalize and standardize evaluation processes for individual CTSA and CTSA Program*
- Advance innovation in education and training programs
- Ensure community engagement in all phases of research
- Strengthen clinical and translational research relevant to child health
- Further engage strategic partnerships with a range of public/private partners (patients groups, industry, foundations, NIH Institutes, etc.)
- Build on the strengths of individual CTSA across the spectrum of clinical/translational research




# What to count? What matters?

IOM CTSA Report released 6/25/13

## Areas of emphasis:

- *Formalize and standardize evaluation processes for individual CTSA and CTSA Program*
- Advance innovation in education and training programs
- Ensure community engagement in all phases of research
- Strengthen clinical and translational research relevant to child health
- Further engage public/private foundations,
- Build on the spectrum of



## **Formalize and standardize evaluation processes for individual CTSA and the CTSA Program**

The evaluations should use clear, consistent, and innovative metrics that align with the program's mission and goals and that go beyond standard academic benchmarks of publications and number of grant awards to assess the CTSA Program and the individual CTSA.

# 15 Consortium Wide Metrics

## ***Data Collection & Analysis***

- Time from IRB submission to approval – IOM studies
- Studies meeting accrual goals
- Time from notice of grant award to study opening (e.g., investigator initiated studies)
- Number of technology transfer products
- Volume of investigators who used services
- Volume of types of services used
- Time to publication
- ROI of pilot and KL2 scholars
- Time from publication to a research synthesis

## ***Impact***

- **Influence** of research publication (e.g., observed/expected citations)
- **Researcher collaboration** (e.g., team science; collaboration index)
- **Career development**
- **Career trajectory** (e.g., K-R transition)
- **Institutional collaboration** (public-private; cross-institutional; community)
- **Satisfaction/needs assessment**



# The workshop

---



# Workshop Outline

- Areas of Focus
  - Scientific Productivity
  - Scientific Collaboration
  - Integration of ICTS Operations
  - Dissemination
  - Impact
- Supporting dissemination and impact
- Open Discussion



Questions?

---

# **Scientific Productivity**

Cathy C. Sarli, MLS, AHIP

Defined as scholarly, peer-reviewed articles authored by ICTS members.

---

# Scientific Productivity


- Data
    - Publication and citation data
      - Databases
      - Self-reported
  - Analysis
    - Bibliometrics
    - Manual review
    - SNA
  - Impact
    - Scientific visibility of publications
    - Change in collaboration or authorship patterns
-

A	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
Authors	Title	Year	Source title	Volume	Issue	Art. No	Page	Page end	Cited by	Link	Affiliation	Authors w	Abstract	Author Ke	Index Key	Molecular	Chemicals	Tradename	Manufact	Funding	Correspon	Editors	Sponsors	Publisher	Conferen
Watts J.A	A soluble	2013	Pulmona	26	2		205	211		http://ww	Departm	Watts, J.	Pulmona	BAY 41-8543	Pulmonary embolism; Pulmonary heart disease; Pulm						Watts, J.A.	Emergency Medicine	Preclinical Re		
Self W.H.	High disc	2013	America	31	2		401	405		http://ww	Departm	Self, W.H	Objective: To evalu	adult; aged; article; bronchopneumonia; computer assis							Self, W.H.	Department of Emergency Medicin			
Venkates	Compute	2013	JAMA Int	173	2		168			http://ww	Departm	Venkates	[No abstract avail	cardiopulmonary hemodynamics; computed tomography							Kabrhel, C.	Massachusetts General Hospital,			
Kline J.A.	Clinical f	2013	Annals o	61	1		122	124	1	http://ww	Departm	Kline, J.A	[No abstract avail	clinical assessment tool; clinical feature; clinical practi							Kline, J.A.	Department of Emergency Medicin			
Heffner /	Predictor	2012	Journal c	27	6		587	593		http://ww	Division	Heffner, /	Objective Complica	beta adrenergic re etomidate, 15301-65-2, 33125-97-2, 51							Heffner, A.C.;	Carolinas Medical Center, Depa			
Lin B.W.,	Therapy ;	2012	America	30	9		1774	1781		http://ww	Departm	Lin, B.W.,	Study Aim: Clinical	anticoagulant agent; fibrinolytic agent; adult; article; bl							Schreiber, D.H.;	Division of Emergency Medicin			
Mitchell	Contrast-	2012	Academi	19	11		1294	1296	1	http://ww	Departm	Mitchell,	[No abstract avail	bicarbonate; creat bicarbonate, 144-55-8, 71-52-3; creatir							Mitchell, A.M.;	Department of Emergency Med			
Than M.,	What is ;	2012	International Journal of Cardiology						1	http://ww	Christchu	Than, M.,	[No abstr	Acceptable risk; Acute myocardial infarction; Early rule out; Emerg							Than, M.;	Christchurch Hospital, Christchurch,			
Puskaric	Plasma I	2012	Shock	38	4		337	340	2	http://ww	Departm	Puskaric	Elevated inflammi	cyclooxygenase 3; cytochrome b, 9035-37-4; reduced nicc							Jones, A.E.;	Department of Emergency Medicin			
Kline J.A.	Thrombo	2012	Journal c	10	9		1973	1974	1	http://ww	Departm	Kline, J.A	[No abstract avail	fibrinolytic agent; Fibrinolytic Agents							Kline, J.A.;	Department of Emergency Medicin			
Kline J.	Failed va	2012	Academi	19	9		1086	1087		http://ww	Departm	Kline, J.,	[No abstract avail	acute coronary syndrome; congestive heart failure; eme							Kline, J.;	Department of Emergency Medicine,			
Heffner /	The frequ	2012	Journal c	27	4	####	4.17E+15		1	http://ww	Division	Heffner, /	Objective Hypotens	beta adrenergic re etomidate, 15301-65-2, 33125-97-2, 51							Jones, A.E.;	Department of Emergency Medicin			
Puskaric	Prognost	2012	Academi	19	8		983	985		http://ww	Departm	Puskaric	Objectives: Previou	lactic acid; adult; a lactic acid, 113-21-3, 50-21-5							Jones, A.E.;	Department of Emergency Medicin			
Penaloza	Risk stra	2012	Current C	18	4		318	325		http://ww	Emergen	Penaloza	PURPOSE pulmona	anticoagulant age apixabar eliquis; pradaxa; xarelto							Penaloza, A.;	Emergency Department, Clinique			
Venkates	Evaluatic	2012	Archives	172	13		1028	1032	4	http://ww	Brigham	Venkates	Background: The ND	dimer; adult; agi Fibrin Fibrinogen Degradation Produ							Kabrhel, C.;	Department of Emergency Medicin			
Moretti S	Autoimm	2012	Journal c	26	7		961	967		http://ww	Departm	Moretti, /	Background Currer	autoantibody; autoimmune marker; biological marker; U							Arunachalam, M.;	Department of Critical Care			
Moretti S	Autoimm	2012	Journal c	26	7		861	867		http://ww	Departm	Moretti, /	Current studies ha	biological marker; Biological Markers							Moretti, S.				
Watts J.A	Proteomi	2012	Thrombo	130	1		122	128	1	http://ww	Departm	Watts, J.	Introduct Haptogl	alpha 2 macroglob alpha 2 macroglobulin, 95568-41-5; fil							Watts, J.A.;	Emergency Medicine Research, Ca			
Kline J.A.	Venous t	2012	Nature R	9	7		378	380		http://ww	Departm	Kline, J.A	The EINSTEIN-PE tr	apixaban; blood cl apixaban, 503612-47-3; blood clotting							Kline, J.A.;	Department of Emergency Medicin			
Penaloza	Performa	2012	Journal c	10	7		1291	1296	1	http://ww	Emergen	Penaloza	Backgrou D-dimer; D dimer; adult; age; aged; article; critically ill patient; fe								Penaloza, A.;	Emergency Department, Clinique			
Arunach	Autoimm	2012	Journal of the European Academy of Dermatology and							http://ww	Departm	Arunacha	Background Although non-segmental vitiligo is commonly considered an a								Arunachalam, M.;	Department of Critical Care			
Than M.,	2-Hour a	2012	Journal c	59	23		2091	2098	7	http://ww	Emergen	Than, M.,	Objective acute cor	troponin I; acceler troponin I, 77108-40-8; Biological Mar							Than, M.;	Emergency Department, Christchurc			
Mitchell	Prospect	2012	Academi	19	6		618	625		http://ww	Departm	Mitchell,	Objectives: Contra	creatinine; hepari creatinin isovue, B Bracco, United Sta							Kline, J.A.;	Indiana University School of Medic			
Kline J.A.	Derivatic	2012	Thrombo	129	5	e194	e199		1	http://ww	Departm	Kline, J.A	Backgrou Decision	adult; article; body mass; breathing rate; controlled stud							Kline, J.A.;	Department of Emergency Medicin			
Hess E.P.	The ches	2012	Circulatio	5	3		251	259	5	http://ww	Departm	Hess, E.P	Backgrou Acute cor	acute coronary syndrome; adult; article; controlled stud							Hess, E.P.;	Department of Emergency Medicin			
Kline J.A.	D-dimer	2012	Journal c	10	4		572	581	5	http://ww	Departm	Kline, J.A	Backgrou Fibrin fra	D dimer; adolesce Biological Markers; Fibrin Fibrinogen							Kline, J.A.;	Department of Emergency Medicin			
Kline J.A.	Prospect	2012	Thrombo	129	4	e25	e28			http://ww	Emergen	Kline, J.A	Objective Decision	heparin; low mole heparin, 37187-54-5, 8057-48-5, 8065-0							Kline, J.A.;	Emergency Medicine Research, Dep			
Puskaric	The auth	2012	Critical C	40	3		1035	1036		http://ww	Departm	Puskaric	[No abstract avail	antibiotic agent; antibiotic therapy; clinical decision m							Puskarich, M.A.;	Department of Emergency Me			
Penaloza	Europear	2012	Journal c	10	3		375	381	1	http://ww	Emergen	Penaloza	Backgrou Compari	adult; aged; article; clinical feature; comparative study;							Penaloza, A.;	Emergency Department, Clinique			
Puskaric	Prognost	2012	Academi	19	3		252	258	5	http://ww	Departm	Puskaric	Objectives: Lactate	activated protein (dobutamine, 34368-04-2, 49745-95-1, 5							Jones, A.E.;	Department of Emergency Medicin			
Watts J.A	Arginase	2012	Pulmona	25	1		48	54	1	http://ww	Departm	Watts, J.A	The expe Arginase	arginase; arginine arginase, 9000-96-8; arginine, 1119-34							Watts, J.A.;	Emergency Medicine Research, Ca			
Kline J.A.	More on	2012	Annals o	59	1		84	85		http://ww	Departm	Kline, J.A	[No abstract avail	clinical decision making; emergency medicine; human;							Kline, J.A.;	Department of Emergency Medicin			
Mitchell	In reply	2012	Academi	19	1		111	112		http://ww	Departm	Mitchell,	[No abstract avail	contrast medium; (creatinine, 19230-81-0, 60-27-5; inulin							Mitchell, A.M.;	Department of Emergency Med			
Kline J.A.	Normaliz	2012	Academi	19	1		11	17		http://ww	Departm	Kline, J.A	Objectives: In a p	acute disease; adult; area under the receiver operating							Kline, J.A.;	Department of Emergency Medicin			
Watts J.A	Pulmona	2011	Critical C	39	12		2700	2704	2	http://ww	Departm	Watts, J.	Objective BAY 41-8	5 2 [1 (2 fluorobenzy hemoglo bay 41 8543							Watts, J.A.;	Department of Emergency Medicin			
Watts J.A	Effects of	2011	Histology	26	10		1287	1294	1	http://ww	Departm	Watts, J.	Right ver Angioten	angiotensin conve angiotensin I, 9041-90-1; dipeptidyl c							Watts, J. A.;	Department of Emergency Medicin			
Puskaric	Outcome	2011	Resusciti	82	10		1289	1293	5	http://ww	Departm	Puskaric	Introduct Lactate; l	lactic acid; aged; a lactic acid, 113-21-3, 50-21-5							Jones, A.E.;	Department of Emergency Medicin			
Puskaric	Associati	2011	Critical C	39	9		2066	2071	17	http://ww	Departm	Puskaric	Objective antibioti	antibiotic agent; l lactic acid, 113-21-3, 50-21-5; Anti-Bac							Jones, A.E.;	Department of Emergency Medicin			
Mitchell	Immedia	2011	Academi	18	9		1005	1009	4	http://ww	Departm	Mitchell,	Objectives: Despit	iopamidol; acute iopamidol isovue 3; Bracco, United Sta							Kline, J.A.;	Department of Emergency Medicin			
Watts J.A	Up-regul	2011	Pulmona	24	4		407	413	4	http://ww	Departm	Watts, J.	Pulmona Arginase	acetylcholine; argi acetylcholine, 51-84-3, 60-31-1, 66-23-							Watts, J.A.;	Emergency Medicine Research, Ca			
Kline J.A.	Risk stra	2011	JNCCN Jo	9	7		800	810	2	http://ww	Departm	Kline, J.A	This arti Acute pu	alteplase; amino (alteplase, 105857-23-6; brain natriure							Kline, J. A.;	Department of Emergency Medicin			
Jones A.E	Cost-effe	2011	Critical C	39	6		1306	1312	3	http://ww	Departm	Jones, A.	Objective cost-effe	activated protein (dobutamine, 34368-04-2, 52663-81-7							Jones, A. E.;	Department of Emergency Medicin			
Jaff M.R.,	Manager	2011	Circulatio	123	16		1788	1830	99	http://www.scopu		Jaff, M.R.	[No abstract avail	alteplase; argatro alteplase, 105857-23-6; argatroban, 7-							Jaff, M. R.				
Pollack C	Clinical c	2011	Journal c	57	6		700	706	28	http://ww	Departm	Pollack, /	Objective anticoag	alteplase; anticoa alteplase, 105857-23-6; enoxaparin, 6							Kline, J. A.;	Department of Emergency Medicin			
Kaji A.H.,	Summary	2010	Annals o	56	5		522	537	5	http://ww	Departm	Kaji, A.H.	Study objective: In	abdominal disease; allergy; clinical research; critical ill							Kaji, A. H.;	Department of Emergency Medicin			

# Publication Data: Annual Capture

## Process:

- Annual publication data capture for ICTS members from *Scopus* via csv. file.
  - Article
  - Conference Paper
  - Review
  - Short Survey
- Each ICTS member has unique ID.
- ICTS members divided into cohorts to track progress over time.
- All ICTS members, former and current, included in the annual publication capture.
- Publication files sent to CPHSS for clean-up



# Publication Data: Challenges

## Challenges with Capture:

- Tracking new and former ICTS members.
- Author disambiguation:
  - Splitting
  - Lumping
- Did we capture all publications?
  - Self-reporting and serendipity

## Challenges with Clean-up:

- Duplicate entries for same record (authorship or database quirk).
    - ISSN
    - PMID
    - DOI
    - Scopus link to record
  - Final manual clean-up required.
-

# Citation Data: Annual Capture and Challenges

## Process:


- Top 50 cited articles from *Scopus* compared to *Web of Science* citation data on annual basis.
- *Web of Science* citation data analyzed using *Essential Science Indicators* on annual basis.
  - Hot Papers
  - Highly Cited Papers
  - Core Papers (Research Fronts)
- Citation data from *Scopus* and *Web of Science* used for reporting and other purposes.

## Definition:

A citation is a reference to a specific publication.

## Challenges:

- Manual process
- Are citations indicative of significance?



THOMSON REUTERS

Essential Science Indicators<sup>SM</sup>  
ISI Web of Knowledge<sup>SM</sup>



# Publication/Citation Data: Five ICTS Examples

- Benchmarking
- Scientific Visibility and Influence
- Authorship Patterns
- Timeframe from Funding to Publication
- Timeframe from Publication to Outcomes

## **Why?**

Narratives of “success stories” based on ICTS-supported research.

<b>Publication Data Elements</b>	<b>2008</b>	<b>2012</b>
Publications in Scopus	2,365	3,160
States represented	49	49
Articles	1,968	2,679
Reviews	288	477
Unique journal titles	938	1,244

### **2008 Top Ten Article Words**

#### **2008 Top Eight Journals**

1. J. of Biological Chemistry
2. J. of Pediatrics
3. American J. of Ob. and Gynecology
4. Blood
5. PNAS
6. J. of Immunology
7. Inf. Control and Hosp. Epidemiology
8. J. of Virology

### **2012 Top Ten Article Words**

#### **2012 Top Eight Journals**

1. PLoS ONE
2. J. of Biological Chemistry
3. PNAS
4. Blood
5. Nature
6. J. of Virology
7. American J. of Ob. and Gynecology
8. Neurology and J. of Neurology (tied)





In 2012, ICTS members co-authored publications with authors from every other CTSA institution (60).




Beau M. Ances, MD, PhD, MSc  
Associate Professor of Neurology at Washington University in St. Louis

*Creutzfeldt-Jakob Disease (CJD) is a rapidly progressive neurodegenerative disease (RPD) with diagnosis often made at autopsy. The goal of this work is to identify early changes in the brain structure due to CJD. This may allow for early intervention.*



PMID: 22968768



**Time from Funding to Publication**



# INITIAL OUTCOMES:


- Increase in knowledge of CJD and RPD.
- Creation of pilot data to support justification for future funding applications.
- New understanding of characterizations of patients with RPD.
- Identification of clinical and diagnostic tests to distinguish CJD from RPD, i.e., MRI and lumbar puncture.
- Identification of new research directions to pursue, i.e., longitudinal studies of pathological changes in CJD.
- Enhanced awareness of RPD and CJD via symposium.
- Recognition from the CJD Foundation as source of knowledge and assistance for patients and families.
- Increase in new referrals of patients as a result of the symposium.



Beau M. Ances, MD, PhD, MSc  
Associate Professor of Neurology

2013

Journal Article  
Sept 2012



# Recap

## Uses of Publication and Citation Data:

- “Snapshot in Time” or Benchmarking.
- Track the 15 Consortium Metrics.
- Identify authorship/collaboration patterns.
- Identify publication practices.
- Identify and highlight promising publications, investigators or studies.
- Grant reporting and renewal purposes.
- Track NIH Public Access Policy compliance.

## Challenges:

- What stories to tell of ICTS success?
  - How and when to best “illustrate” numerical data.
-

Questions?

---



**BREAK**

---

# Scientific Collaboration

Bobbi Carothers, PhD

Defined as activities that stem from ICTS scientific productivity.

---

# Why Care About Collaboration?

- ICTS Aim 3: Assess the growth in scientific and institutional collaborations and communication as a function of ICTS activities
  - Medical science is a collaborative process
  - Necessary for translation from bench to practice & populations
-

# Collaboration Model


- Plan to work together
- Work together
- Disseminate results of the work



# Collaboration Networks

- Data: Links between investigators
    - Grant Submissions
    - Research Collaborations
    - Publication Co-authorships
  - Analysis: Social Network Analysis
    - Number of collaborations
    - Cross-discipline mix
  - Impact: Change over time
-

# DATA



# Collection

Relationship	Method	Frequency
Grant Submission	Administrative Records	Every 2 Years
Research Collaboration	Online Survey of Members (Qualtrics)	Every 2 Years
Publication Co-authorship	Literature Review	Annually


---

# Grant Submissions


Raw Data

Member ID	Grant ID
11	21
12	21
13	21
13	22
14	22
15	22

Relationships between people & grants



Relationships between people





# Research Collaborations

## Raw Survey Data


Participant	Collaborator 1	Collaborator 2	Collaborator 3
Jane	Mark	John	Dana
Mark	Jane	Dana	

↓ Participant/  
Collaborator

Participant	Collaborator
Jane	Mark
Jane	John
Jane	Dana
Mark	Jane
Mark	Dana



## Network



# Publication Co-authorships


- Managed similarly to grant submissions

Raw Data

Member ID	Publication Title
11	Cool cancer treatment report
12	Cool cancer treatment report
13	Cool cancer treatment report
13	Nifty Alzheimer's gene report
14	Nifty Alzheimer's gene report
15	Nifty Alzheimer's gene report



Relationships



# Challenges

- Research Collaborations
    - 1400 members → too many for participants to hunt through a drop-down list in order to find collaborators
    - Participants write in the names of their collaborators
      - Many are not ICTS members
      - Creative spelling
    - Labor-intensive data cleaning
  - Publication Co-authorships
    - Variations in publication titles require cleaning
    - Not all publications appear with DOI or PubMed ID
-

# **SOCIAL NETWORK ANALYSIS**

Visualizations

Relationship Patterns


---

# Grant submission network (2007)

- Before ICTS grant
- Discipline denoted by color

Out of 387 members

# Submitted grants	236
Average # of collaborators	1.92
Cross-discipline to within-discipline collaboration density ratio	.216



# Publication Co-authorship Network (2007)

Out of 387 members

# Published


221

Average # of collaborators

2.02

Cross-discipline to within-discipline collaboration density ratio

.191





# IMPACT

So what?

Change over time

---

# Grant Submissions, 2007 vs. 2010




Year	# Members	Average # Collaborators	Cross- to Within-discipline Collaboration Density Ratio
2007	236	1.92	.216
2010	257	4.81	.436





# Publication Co-authorships, 2007 vs. 2010



Year	# Members	Average # Collaborators	Cross- to Within-discipline Collaboration Density Ratio
2007	221	2.02	.191
2010	256	2.64	.230



# Conclusions: Does ICTS Improve Collaboration?

- Increase in number of people submitting grants and getting published
  - Increase in number of collaborators
  - Increase in cross-disciplinarity of collaborations
  - Pattern less strong for publications than grants likely due to lag time
  - Second research collaboration survey to occur in the fall
-

# RESOURCES


What we used

Where to get it


---

# Software

Pajek



UCInet



R/Statnet



- All are frequently updated

# Links

- Pajek: <http://pajek.imfm.si/doku.php?id=pajek>
  - Qualtrics: <http://www.qualtrics.com/>
  - Statnet:  
<http://statnet.csde.washington.edu/index.shtml>
  - UCINet:  
<https://sites.google.com/site/ucinetsoftware/home>
-

Questions?

---

# Integration of ICTS Operations

Elizabeth Palombo, MEd

Defined as integration of services and activities of ICTS within WU & resulting satisfaction by ICTS members, removal of barriers to conduct TR, more efficient TR activities, etc.

---

# ICTS Operations

- **Data:**
    - Surveys
    - Service Use
    - Membership
  - **Analysis:**
    - Survey reports
    - Cross-disciplinary tables
    - Dashboards
  - **Impact:**
    - Enhance ICTS core services
    - Core/service funding allocation
    - Translational Research education
    - Reporting to ICTS Governance and NCATS/NIH
-



# Improve Member Research Experience and Reduce Barriers



# DATA: Member & Satisfaction Surveys

- **Methodical Plan**
    - Avoid over-surveying
    - Helps with maintaining history and consistency
  - **Survey Purposes**
    - Satisfaction with cores and services
    - Marketing of ICTS, cores and services
    - Program evaluation
    - Core specific as requested
  - **Beyond the ICTS**
    - Siteman Cancer Center
    - CTSA Evaluation Key Function Group
-

# Standardized Core Questions

1. Rate core satisfaction on:
    - Process to request services
    - Timeliness of services received
    - Quality of the services received
  2. Rate satisfaction with the core services
  3. Would you use the core services again?
  4. Comments
-

# DATA: ICTS Service Use

- Purpose? Why is it important?
  - How is it reported?
    - Core Evaluation Coordinators
    - Service Tracker
    - Excel Spreadsheet
  - What is included?
    - Investigator Information
    - Service Details
    - Project Information
-

# DATA: Core Service User Departmental Distribution

Human Imaging Unit (HIU)  
Service Use 9/17/07-2/15/13

Institution/School/ Department	Year of Use					
	1	2	3	4	5	6
Saint Louis University (SLU)					1	
Washington University (WU)						
Arts & Sciences		2	4	4	4	6
Engineering		1	2	2	4	3
Anatomy & Neurobiology			1			1
Anesthesiology			1	3	4	3
Internal Medicine	6	26	27	28	32	26
Neurological Surgery			1	1	2	4
Neurology	7	18	21	20	21	23
Obstetrics & Gynecology				2	2	2
Occupational Therapy		1	1			
Ophthalmology & Visual Sciences		1	1			
Orthopaedic Surgery		3	6	3	5	4
Otolaryngology		1	1	2	4	1
Pediatrics	2	5	10	12	12	10
Physical Therapy	1	2	4	5	5	5
Psychiatry	2	7	11	10	8	7
Radiation Oncology	2	2	3	4	4	4
Radiology	9	13	18	20	23	25
Surgery	2	7	9	8	8	5
<b>Total Unique Users Each Year</b>	<b>31</b>	<b>89</b>	<b>121</b>	<b>124</b>	<b>139</b>	<b>129</b>

*220 Unique investigators used HIU  
Services over 6 years*

# ANALYSIS: Cross-Disciplinary

## ICTS Current Membership

Institution	Number of Members
<b>Nursing Schools</b>	
Goldfarb School of Nursing <i>(excluded from BJH total below)</i>	7
Saint Louis University (SLU) <i>(excluded from SLU total below)</i>	4
Southern Illinois University Edwardsville (SIUE)	11
University Of Missouri - St. Louis (UMSL)	15
<b><i>Nursing Schools Subtotal</i></b>	<b>37</b>
<b>Barnes Jewish Hospital (BJH)</b>	<b>21</b>
<b>Community Organizations</b>	<b>6</b>
<b>St. Louis Children's Hospital (SLCH)</b>	<b>2</b>
<b>St. Louis College of Pharmacy (STLCOP)</b>	<b>36</b>
<b>Saint Louis University (SLU)</b>	<b>128</b>
<b><i>Partner Institutions Subtotal</i></b>	<b>230</b>
<b>Washington University (WU)</b>	
<b><u>Danforth Campus</u></b>	
Arts & Sciences	23
Olin Business School	4
School of Engineering & Applied Science	14
Brown School of Social Work	32
<b><i>Danforth Campus Subtotal</i></b>	<b>73</b>

<b><u>School of Medicine</u></b>	
<b>Preclinical Departments</b>	
Anatomy & Neurobiology	6
Biochemistry & Molecular Biophysics	8
Cell Biology & Physiology	8
Developmental Biology	12
Genetics	29
Molecular Microbiology	11
<b><i>Preclinical Departments Subtotal</i></b>	<b>74</b>
<b>Other School of Medicine Departments/Units</b>	
Administrative	6
Anesthesiology	31
Audiology & Communication Sciences	3
Biostatistics	10
Internal Medicine	292
Neurological Surgery	19
Neurology	68
Obstetrics & Gynecology	40
Occupational Therapy	21
Ophthalmology & Visual Sciences	27
Orthopaedic Surgery	48
Otolaryngology	31
Pathology & Immunology	56
Pediatrics	138
Physical Therapy	28
Psychiatry	52
Radiation Oncology	26
Radiology	53
Surgery	89
<b><i>School of Medicine Subtotal</i></b>	<b>1112</b>
<b><i>Washington University Total</i></b>	<b>1185</b>
<b>Grand Total</b>	<b>1418</b>

# ANALYSIS: Survey Reports

- Types of Reports
    - Executive Summary
    - Tailored to specific audience (membership, program directors)
  - Feedback Loop
    - Reporting to membership
    - Let them know we value their responses and time
    - Present examples of change because of responses
-

# ICTS Member Satisfaction Survey Results

## About the Survey:

- Distributed February 28 – April 5, 2013
- Year 4 of ICTS/Siteman Cancer Center (SCC) collaborative effort
- Anonymously distributed through Qualtrics via email to ICTS/SCC members

<b>2013</b>	<b><i>ICTS Members Surveyed</i></b>	<b><i>SCC Members Surveyed</i></b>	<b><i>Total Surveys</i></b>
Distribution	<b>1418</b>	274	<b>1485</b> (duplicates removed)
Responses/ Rate	<b>613/43%</b>	<b>179/65%</b>	<b>642/43%</b>

- ICTS response rates: 43% in 2013, 54% in 2011, 38% in 2010, 28% in 2009
  - Names associated with completed surveys entered into random drawing
  - 6 prizes issued - *iPad (1) & B&N \$20 Gift Card (5)*
- Core Director response/survey results to be discussed with director at their next scheduled meeting with Drs. Evanoff and Moley



# ICTS Core Service Satisfaction

**4.35 = Mean Core Satisfaction Score**


Core Name	ICTS Service Users	Responses	2013 Mean Satisfaction	2011 Mean Satisfaction
Core 1	97	171	4.16	4.17
Core 2	36	33	4.33	4.33
Core 3	18	20	3.81	4.25
Core 4	27	29	4.54	4.26
Core 5	27	8	4.90	4.56
Core 6	129	62	4.40	4.28
Core 7	43	46	3.89	3.92
<b>No Services Used</b>	-	<b>280</b>	-	-

1=Very Dissatisfied
2=Somewhat Dissatisfied
3=Neither Satisfied nor Dissatisfied
4=Somewhat Satisfied
5=Very Satisfied

**Number of Different Cores Used by Investigators as Reported in Survey**

# Different Cores Used	1	2	3	4	5	6	7	8
Investigators	203	121	51	22	11	9	5	5

# Investigators Benefited from the ICTS Cores and Services



# Most Helpful Services Received from the ICTS Cores?

*(Check all that apply)*

	# Responses	% of Respondents
<b>Collaboration</b>	<b>130</b>	<b>24%</b>
<b>Technical support for data management and/or analysis</b>	<b>127</b>	<b>24%</b>
<b>Proposal Development</b>	<b>108</b>	<b>20%</b>
<b>Participant Recruitment</b>	<b>81</b>	<b>15%</b>
<b>Funding</b>	<b>68</b>	<b>13%</b>
<b>Access to Data</b>	<b>64</b>	<b>12%</b>
<b>Training / Education</b>	<b>58</b>	<b>11%</b>
<b>Support for IRB and/or compliance issues</b>	<b>48</b>	<b>9%</b>
<b>Other</b>	<b>48</b>	<b>9%</b>

# 15 Consortium Wide Metrics

## ***Data Collection & Analysis***

- Time from IRB submission to approval – IOM studies
- Studies meeting accrual goals
- Time from notice of grant award to study opening (e.g., investigator initiated studies)
- Number of technology transfer products
- Volume of investigators who used services
- Volume of types of services used
- Time to publication
- ROI of pilot and KL2 scholars
- Time from publication to a research synthesis

## ***Impact***

- **Influence** of research publication (e.g., observed/expected citations)
- **Researcher collaboration** (e.g., team science; collaboration index)
- **Career development**
- **Career trajectory** (e.g., K-R transition)
- **Institutional collaboration** (public-private; cross-institutional; community)
- **Satisfaction/needs assessment**

# ANALYSIS: Dashboards

#	Outcomes Metrics to Dashboards	ICTS Aim	Type of Data	Value of Information	Level of Difficulty
1	Time from IRB submission to approval	1	Research/clinical	***	+
2	Studies meeting accrual goals	1, 3	Research/clinical	***	++
3	Time from notice of grant award to study opening (investigator initiated studies)	1, 3	Research/clinical	***	+++
4	Number of technology transfer products	1, 3	Admin	***	++
5	Volume of investigators who used services	1	Service	****	+
6	Volume of types of services used	1	Service	****	+
7	Satisfaction/Needs assessment	1	Service	***	+
8	Time to publication (need to define time)		Pubs	*	++++
9	Influence of research publication (observed/expected citations)	3	Pubs	****	++
10	Researcher collaboration (team science; collaboration index)	3	Admin	****	++
11	ROI of pilot and KL2 scholars	all	Admin	****	+++
12	Time from publication to a research synthesis		Pubs	***	++++
13	Career development	2	Education	***	++
14	Career trajectory (includes K-R transition)	2	Education	***	++
15	Institutional collaboration (public-private; cross-institutional; community)	3	Admin	***	++++

Value of Information: \*\*\*\* = High Value \* = Low Value

Level of Difficulty: + = Low Difficulty ++++ = High Difficulty

# T&E Effect on ICTS Operations

- Enhance ICTS Services
    - Services added
    - Improved service delivery
    - Certain expertise added to meet needs
  - Core/Service Funding
    - Funding direction can change based on:
      - Feedback or service demands
      - Distribution of service users
  - Translational Research
    - Introducing a new way of thinking
    - Emphasis on moving research from one stage to next
    - Communicating that ICTS cores, staff and resources can help investigators go further with research
-

Questions?

---

# Dissemination

Kristi Holmes, PhD

Defined as an active approach of spreading evidence-based interventions to the target audience via determined channels using planned strategies.



# Some thoughts about dissemination

## What is dissemination?

- Dissemination is an active approach of spreading evidence-based interventions to the target audience via determined channels using planned strategies.
- For the purpose of this workshop, we are also including the process of communicating results/findings to the general public or funding agencies or other stakeholders as **DISSEMINATION**.

# Some thoughts about dissemination

## Dissemination Strategies for varied stakeholders

- Dissemination strategies describe mechanisms and approaches that are used to communicate and spread information about interventions to targeted users.
- Dissemination strategies are concerned with the packaging of the information about the intervention and the communication channels that are used to reach potential adopters and the target audience.
- It is consistently stated in the literature that dissemination strategies are necessary but not sufficient to ensure widespread use of an intervention.

*Putting it into practice...*

# Some thoughts about dissemination

## Examples of dissemination

- **Passive dissemination strategies** include mass mailings, publication of information including practice guidelines, and untargeted presentations to heterogeneous groups.
- **Active dissemination strategies** include hands-on technical assistance, replication guides, point-of-decision prompts for use, and mass media campaigns.

## Motivations – Why disseminate?

CRITICAL to communicate findings to various stakeholders – researchers, potential collaborators, partners, members of the public, funders, other consortium members, policy makers, and so on...

---



Beau M. Ances, MD, PhD, MSc  
Associate Professor of Neurology at Washington University in St. Louis

Creutzfeldt-Jakob Disease (CJD) is a rapidly progressive neurodegenerative disease (RPD) with diagnosis often made at autopsy. The goal of this work is to identify early changes in the brain structure due to CJD. This may allow for early intervention.



PMID: 22968768



Journal Article



2009

2012

2010


2011

2013

Awarded J1T funding from ICTS to study Creutzfeldt-Jakob Disease (CJD): **Diffusion Tensor Imaging (DTI) as an Early Biomarker of Cruetzfelt-Jakob Disease (CJD)**

**FINDINGS:**  
Study results confirmed that cerebrospinal fluid abnormalities and magnetic resonance imaging (MRI) can assist in distinguishing CJD patients from non-prion RPD patients, calling for future longitudinal studies to evaluate pathological changes seen in CJD patients.

Hosted Symposium



**Evaluation of Creutzfeldt-Jakob Disease (CJD) & Other Rapidly Progressive Dementias**

October 23, 2012 8:00 AM – Noon  
Washington University School of Medicine  
Eric P. Newman Center

9:50-10:10 AM The Role of MRI in the Diagnosis of CJD (Beau Ances MD, PhD, MSc)

Length of time from funding to publication

# Impact

Kristi Holmes, PhD

Defined as successful completion of research and communication of discoveries that leads to changes in knowledge and clinical practice.

---

# Impact?? HOW do you measure that?

- Why measure? How to measure?
- What things do people typically count?
- What things should you measure?

*“It is no longer enough to measure what we can – we need to measure what matters.”*

**How do we measure what matters?**



Wells R, Whitworth A. 2007. Assessing outcomes of health and medical research: do we measure what counts or count what we can measure? *Australia and New Zealand Health Policy*, 4:14

# A great resource: the RAND Report

- [Measuring Research: A Guide to Research Evaluation Frameworks and Tools](#)
  - AAMC commissioned a report from the RAND Corporation
  - Summarizes current conceptual models for how biomedical research translates into academic, health, social and economic impacts, and profiles 14 robust research evaluation initiatives already in use
  - Includes a detailed and critical review of a host of tested and documented assessment tools, which can be used for various purposes--whether for advocacy, accountability, analysis or internal allocation decision-making.
  - A related [research brief](#) is also available.



# Tools

- **bibliometrics:** a range of techniques for assessing quantity, dissemination and content of publications and patents; uses quantitative analysis to measure patterns of publication and citation, typically focusing on journal papers
- **surveys:** provide a broad overview of the current status of a particular program or body of research; widely used in research evaluation to provide comparable data across a range of researchers and/or grants which are easy to analyze
- **logic models:** graphic representation of the essential elements of a program or process; aims to encourage systematic thinking and guide planning, monitoring and evaluation
- **case studies:** can be used in a variety of ways; flexible enough to capture a wide variety of impacts, including the unexpected, and can provide the full context around a piece of research, researcher or impact
- **economic analysis:** comparative analysis of costs (inputs) and consequences (outputs); aims to assess whether benefits outweigh opportunity costs and whether efficiency is achieved; generally, there are three types of economic analysis: cost-benefit analysis (CBA), cost-effectiveness analysis (CEA) and cost-utility analysis (CUA)
- **peer review:** review by peers, typically other academics in the same or a similar field, of outputs of research; rationale that subject experts are uniquely qualified to assess the quality of the work of others
- **data mining:** allows access to and understanding of existing data sets; uses algorithms to find correlations and patterns and present them in a meaningful format, reducing complexity without losing information
- **interviews:** used to obtain supplemental information on areas of interest, generally to access personal perspectives on a topic, or more detailed contextual information
- **data visualization:** tool for data summarization, presenting large amounts of data in a visual format for human comprehension and interpretation
- **site visits:** visit by evaluating committee to department and institution; generally consists of a series of meetings over one or more days with a range of stakeholders
- **document review:** review of existing documentation and reports on a topic.

What is it?  
When should it be used?  
How is it used?





# Frameworks

- Canadian Academy of Health Science Payback Framework (Canada)
- Excellence in Research for Australia (ERA) (Australia)
- National Institute of Health Research Dashboard (England)
- Research Excellence Framework (REF) (UK)
- Productive Interactions (Netherlands and European Commission).
- Science and Technology for America's Reinvestment: Measuring the Effect of Research on Innovation, Competitiveness and Science (STAR METRICS) (US)
- Several others...

Origin and rationale  
Scope  
Measurement  
Application to date  
Analysis  
Wider applicability







# Pathways

- ✓ Advancement of Knowledge
  - ✓ Clinical Implementation
  - ✓ Legislation and Policy Enactment
  - ✓ Economic Benefit
  - ✓ Community Benefit
-

# The Becker Model

- Provides a supplement to publication analysis to provide a more robust and comprehensive perspective of biomedical research impact.
    - reporting templates, glossary of resources and terms, examples of relevant indicators of impact across the research process, readings, and a sample of a completed report
  - Straightforward framework for tracking diffusion of research outputs and activities to locate indicators that demonstrate evidence of biomedical research impact
    - individual, core, and institutional-level; modify for different disciplines
  - Guidance for quantifying and documenting research impact as well as resources for locating evidence of impact.
  - Strategies for **enhancing** the impact of research.
    - *Preparing for Publication, Dissemination, and Keeping Track of Your Research*
-

# Project Website

## ASSESSING THE **IMPACT** OF RESEARCH

A Bernard Becker Medical Library Project

THE MODEL //  
HOW TO USE //  
ENHANCING YOUR IMPACT //  
INFORMATION AND RESOURCES //

THE MODEL FOR ASSESSMENT OF RESEARCH IMPACT IS A FRAMEWORK FOR **TRACKING DIFFUSION** OF RESEARCH OUTPUTS AND ACTIVITIES TO LOCATE INDICATORS THAT DEMONSTRATE EVIDENCE OF BIOMEDICAL RESEARCH IMPACT.

### **Research Output and Activities**

What was **CREATED** by a research study? How was the research output **DISSEMINATED**? What activities were **UNDERTAKEN** by the members of the research group?

### **Advancement of Knowledge**

How were research output and activities **USED**? How was **AWARENESS** of research output demonstrated?


### **Clinical Implementation**

How was **TRANSLATION** of research output and activities into clinical applications demonstrated?



<https://becker.wustl.edu/impact-assessment>

# Implementation of Becker Model

- Case Study 
  - Select 3-5 for further analysis
- Operationalize application of the Becker Model
  - Make it replicable and scalable at other sites
  - Develop an SOP or “product” for others to use.

## Target Sample Criteria:

- Member of ICTS
- Recipient of JiT or Pilot funding from ICTS or K12 support
- ICTS member with high levels of collaboration (in renewal document)
- A mix of ICTS members at various career stages including scholars
- ICTS members (at least one bench, one clinical) and one project group such as a Core Facility that has received or is currently receiving funding from ICTS
- Suggestions by T&E Team, and ICTS PIs and administrators



# Implementation of Becker Model

## Seminar Series for Investigators and Scholars and/or Recipients of ICTS Funding

### NIH Public Access

- Recipients of ICTS funding are required to cite the ICTS award in peer-reviewed publications that result from ICTS funding. This session will provide an overview of the NIH Public Access Policy including the steps involved in complying with the policy and how to demonstrate compliance.

### Optimizing Dissemination of Research

- Optimizing discoverability and access of research findings is the surest way to enhance visibility and impact of ICTS research efforts. This session will review a variety of strategies for investigators and scholars to consider as they prepare to disseminate their research.

### Reporting Impact

- The ability to effectively demonstrate Return on Investment (ROI) and impact is essential for ICTS reporting purposes and can also be a very valuable component of promotion and tenure activities. This session will describe how investigators and scholars can effectively report on impact and “success stories” from ICTS funding using publication data, grant application/award data, new or promising discoveries, collaborations, and other information.




Translating this into your own  
environment...

---



# A decision tree for developing a research evaluation framework



Group 1 tools: case studies, documentary review, site visits, peer review

Group 2 tools: bibliometrics, economic analysis, data mining

Also need to consider

**Level of aggregation:** What unit of data reporting, collection and analysis will you use?  
Reporting ≥ analysis ≥ collection


**Context:** Who are your stakeholders? What will be credible and acceptable to them? What has been done before?

**Implementation:** Do you have strong central ownership? What burden does the framework place on participants, and how are they supported and incentivised to participate?

Translating this into your own environment

# Partnerships for Environmental Public Health (PEPH) Evaluation Metrics Manual

- NIEHS Division of Extramural Research and Training
- Ideas about how to measure and document success



Sample metrics from grantee programs include:

- **Demonstrating success at identifying partners** — The University of Cincinnati's anti-idling campaign provided a *description of the partners involved and the resources they bring to the project*. Cincinnati Public Schools (CPS) provided access to students and schools, Cincinnati Health Department provided nursing services, a Councilwoman provided credibility and the ability to attract attention to the project, and the Hamilton County Department of Environmental Services provided training and information to CPS staff and students.
- **Demonstrating that they communicated their findings in a variety of products** — The Bay Area Breast Cancer and the Environment Research Center described the number and demographics of their *social media audience*. The center has more than 1,000 followers on twitter and 864 Facebook friends. Followers are 70 percent female and more than half are age 40 or older.
- **Demonstrating the policy impacts of their advocacy** — The Trade, Health, and Environment Impact Project at the University of Southern California documented its contribution to the formation of the San Pedro Bay Ports Clean Air Action Plan. The plan stated that the Ports of Los Angeles and Long Beach would reduce air pollution by 45 percent by 2011. The project also documented its involvement in passing the Clean Air Action Plan, which established a progressive ban on polluting trucks. *The plan resulted in a 70 percent reduction in port truck emissions in the Port of Los Angeles in the first year.*

Questions?

---

# Supporting Dissemination & Impact

Jae Allen, MBA

Strategies and people.

---

# T&E Team Role

- Strategy: Develop, describe & implement T&E aims and procedures to measure impact of the WU CTSA
  - Data: Collect, clean and store information
    - Data elements (ex. publications, grants received)
    - Examples of successful research (vignettes)
  - Analysis: Apply our diverse areas of expertise to analyze information and develop representations (graphs, tables, charts)
-

# T&E Team Role, continued

- *Illustrate*: Weave the various representations into a description of impact
  - *Disseminate* our findings through multiple communication channels
-

# Weaving the Tapestry of Impact

Describing Impact, to date:

- Built infrastructure to support clinical & translational research (Elizabeth)
- Broke down barriers to increase research collaborations (Cathy & Bobbi)
- Measured quality and extent of clinical & translational science (Cathy)

**How do we take the next step of describing IMPACT?**

---

# New Initiatives

- New Resources
    - Navigation Resources (Betsy Keath, PhD)
    - Research Forums (John Kotyk, PhD)
  - Return on Investment for Funding Programs
  - Becker Model Implementation
-



# New Resources

- Personalized Consultation (Dr. Keath)
  - Research and Teaching Experience
    - Experience as lead investigator, educator and mentor in University setting (20+ yrs)
    - Participated in scientific review on national study sections (6 yrs)
  - Scientific Programme Officer for Science Foundation Ireland
  - Consultant for Irish Cancer Society
    - Needs assessment
    - Gap analysis on priority topics to influence agency policy
- eNavigator Portal

<http://www.icts.wustl.edu/icts-researchers/icts-cores/contact-icts-navigator>

---

# New Resources, cont.

- Research Forum – Child Health (Dr. Kotyk)
    - Pharmaceutical Industry, Research Fellow (17 years)
      - Research – drug discovery and development
      - Project management
    - Research Associate Professor of Radiology (8 years)
      - Helped create the WU Center for Clinical Imaging Research
      - Established the ICTS Human Imaging Unit
      - Protocol/Project development
  - Personal connections to the success stories
-

# Annual ROI Analysis

- Annual Clinical & Translational Awards
    - ~20 awards, ~ \$50,000
  - Progress Reports & Annual Surveys (5 yrs post)
    - External Grants Submitted
    - External Grants Awarded
    - Publications
-

# Pilot Program ROI

# Years Post Award	External Funding, in Millions	# External Grants
1	\$10.2	10
2	\$27.7	25
3	\$46.7	40
4	\$47.2	41

**Return of \$5.51 per dollar spent on the program over 5 years.**

---

# Dissemination & Communication Channels

---

# ICTS Website: Audiences



Institute of **C**linical and  
**T**ranslational **S**ciences

For  
ICTS Researchers

For  
Community Partners

For  
The Public

OVERVIEW

EDUCATION

NEWS & EVENTS

RESEARCH PARTICIPATION

Accelerating Discoveries Toward  
Better Health



## Shortcuts

- Healthy Living Tips
- Your Disease Risk
- How Research Works
- Volunteer for Research



Subscribe to  
email updates »

## Spotlight

Save the date! Our Community, Our Health presents

**Community/University**

**Partnerships: Potential Impacts on Health** - Friday, May 31 at the Missouri History

## News

**Medication plus talk therapy for anxiety in seniors** - A study of older adults has found that combining antidepressant medication with a type of psychotherapy called cognitive behavioral therapy (CBT) appears to be very effective as a treatment for anxiety. [MORE »](#)

**U.S. News & World Report ranks best children's hospitals 2013-14** - St. Louis Children's Hospital, Washington University ranked as the sixth best children's hospital in the nation. [MORE »](#)

**Convenience steers parents to pediatric retail clinics, study finds** - Convenience is the main reason why parents with a regular pediatrician will take their children to health clinics in large chain drug stores or other retail locations, a new study finds. [MORE »](#)

[NEWS ARCHIVE](#)

[Newsletter \(pdf\)](#) [Back Issues](#)

## Events

[view full calendar](#)

### ICTS Partners

Washington University in St. Louis  
BJC Healthcare

Washington University School of Medicine  
Campus Box 8066  
660 S. Euclid Ave.  
St. Louis, MO 63110-8066

### FAQs

[Related Links](#)

# ICTS Website: Impact Section

Washington University in St. Louis National CTSA »

 **Institute of Clinical and Translational Sciences**

**For ICTS Researchers**   **For Community Partners**   **For The Public**

**ABOUT   ICTS CORES   EDUCATION   FUNDING   TOOLS & RESOURCES   IMPACT   NEWS & EVENTS**

FOR ICTS RESEARCHERS > IMPACT

**Return on Investment**

**Collaboration**

**Publications**

**Education**

## Impact



Quantifying the impact and relevance of translational research is an evolving discipline and evaluating the impact of the ICTS requires a multi-faceted approach. In cooperation with CTSA institutions, the National Institutes of Health has provided insight about metrics to inform a national audience and about several metrics meaningful for measuring local impact.

Given those guidelines and other metrics needed to inform the many ICTS stakeholders, the ICTS Tracking & Evaluation team has implemented several processes for capturing and analyzing data about ICTS investigators, their research and resulting discoveries. Examples of those analyses are categorized and available through the menu on the left.

**ICTS Partners**

Washington University in St. Louis  
BJC Healthcare

- Barnes-Jewish Hospital
- St. Louis Children's Hospital
- Goldfarb School of Nursing

St. Louis College of Pharmacy  
Saint Louis University  
Southern Illinois University Edwardsville,  
School of Nursing  
University of Missouri at St. Louis  
College of Nursing

Washington University School of Medicine  
Campus Box 8066  
660 S. Euclid Ave.  
St. Louis, MO, 63110-1093  
Phone: 314.362.9829  
Fax: 314.362.8015  
Email: icts@dom.wustl.edu

**FAQs**

**Related Links**

**Sitemap**

**Contacts**

**Feedback**

Supported by CTSA Grant  
UL1 TR000448.  
See the entire funding

# WU Public Affairs (Outlook Magazine)

Washington University in St. Louis  
School of Medicine MAGAZINE **Outlook** APR 2013 CONTENTS →

## seeds of discovery

funding initiative speeds innovation to improve health

Each dot denotes a faculty member of the ICTS, and each connecting line represents a collaboration between faculty in submitting an NIH grant application. ICTS began in 2007, above left, and by 2010, above right, there had already been a dramatic increase in the number of collaborations and the density of interconnections among research groups.

BY JULIA EVANGELOU STRAIT

**Whether providing pilot funding to gather initial data or final funding for projects heading toward publication,** grants awarded by Washington University's Institute of Clinical and Translational Sciences (ICTS) are ultimately aimed at one goal — supporting medical research that has the highest likelihood of benefiting patients quickly.

"Facilitating new research collaborations across traditional disciplinary



# Outlook Magazine

Kelle H. Moley, MD

better  
infant care

mothers' tissue samples  
illuminate children's  
diseases



[READ MORE](#)

Randall S. Sterkel, MD,  
and Jene M. Garbutt,  
MBChB

into the  
community

aiming for consensus in  
private practice clinical  
care



Matthew J. Ellis, MD, PhD

advanced  
resources

modeling deadly cancers  
may lead to new  
treatments



[READ MORE](#)

Robert C. McKinstry, MD  
PhD, and Pamela K.  
Woodard, MD

bright  
outlook

high-tech imaging  
bridges research and  
application



[READ MORE](#)

# Dissemination: Communication Channels

- Monthly “ICTS Digest”: email with links to website updates
  - Emails to Members
  - Scholarly works (posters and publications)
  - Annual Progress Reports
-

# Benefit at Multiple Levels

- Individual: highlights accomplishments and documents career progression
  - ICTS: illustrates value & informs decision making
  - Institution: enhances intra-institutional connections, strategic value for Washington University
  - Consortium: illustrates value and impact of national community health research, inter-institutional with local partners
-

# How do YOU illustrate Impact?

Sharing roundtable discussion.

---

# Open Discussion

Sharing roundtable discussion.

---

# Credits

- <http://www.performanceobjectivesnow.com/blog/wp-content/uploads/2011/09/po4steps.jpg>
  - [http://wsfcs.k12.nc.us/cms/lib/NC01001395/Centricity/Domain/926/Pictures/course\\_outline2.jpg](http://wsfcs.k12.nc.us/cms/lib/NC01001395/Centricity/Domain/926/Pictures/course_outline2.jpg)
  - <http://1.bp.blogspot.com/-BZNfDFAW5vs/TgyStWZT-ol/AAAAAAAAAOo/KbpJort-6dl/s1600/speaking-at-podium1.jpg>
-

# Acknowledgement

Supported by the Clinical and Translational Science Award (CTSA) program of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH)  
Grant Numbers UL1 TR000448, KL2 TR000450, TL1 TR000449

---